title: PARP inhibitors and more.
abstract: Polyadenosine diphosphate (ADP) ribose polymerase (PARP) lends a panoramic view to the inner mystery of protection of integrity of deoxyribonucleic acid (DNA) in a cell genome. They are a balancing part of an even more dynamic equilibrium of normalcy against daily assaults. PARP finds its companion candidates in other tumor suppressors, with the most prominent and glaring one being breast cancer (BRCA) 1 and 2. The strength of both is split by PARP inhibitors, inculcating the synthetic lethality of tumor cell, which is now in the market for ovarian cancer treatment. There are many reasons for the resistance of such inhibitors, which are now becoming clinically important. These are seen along with other damage repair approaches.
authors.affiliation: Department of Gynecological Oncolgy, Division of Clinical Trial, Netaji Subhas Chandra Bose Cancer Research Institute, West Bengal, India.
authors.forename: Chinmoy K
authors.initials: CK
authors.lastname: Bose
authors.affiliation: 5 Year MBBS Student, Calcutta Medical College, West Bengal, India.
authors.forename: Nirban
authors.initials: N
authors.lastname: Basu
keywords: BRCA; PARP inhibitors; olaparib; ovarian cancer; synthetic lethality